Skip to content
DataLookout
Menu

EXTENSANCT07919899

Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) Coformulation

StatusNot Yet Recruiting
PhasePhase 3
SponsorSanofi
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Ctrough,ss at Week 20
Timeframe: Week 20

Secondary (6)

AUC0-4 weeks,ss
Cmax,ss
Incidence of TEAEs, TE-AESIs, TE-SAEs, and TEAEs leading to permanent treatment discontinuation in the treatment-emergent period
Incidence of potentially clinically significant abnormalities in laboratory test, vital signs, and ECGs abnormalities in the treatment-emergent period
Incidence of treatment-emergent anti-drug antibody (ADA) to dupilumab through Week 20
Show 1 moreShow less
Incidence of treatment-emergent ADA to ALT-B4 through Week 20

Arms and interventions

Dupilumab coformulated with berahyaluronidase alfaExperimental

dupilumab coformulated with berahyaluronidase alfa SC injection as per protocol

Dupilumab approved formulationActive comparator

Approved dupilumab SC injection as per protocol

Drugs: Dupilumab coformulated with berahyaluronidase alfa, Dupilumab